Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial

Autor: Andrieux-Meyer, Isabelle †, a, *, Tan, Soek-Siam †, b, Thanprasertsuk, Sombat †, c, Salvadori, Nicolas d, Menétrey, Caroline a, Simon, François a, Cressey, Tim R d, e, Said, Hajjah Rosaida Hj Mohd f, Hassan, Muhammad Radzi Abu g, Omar, Haniza b, Tee, Hoi-Poh h, Chan, Wah Kheong i, Kumar, Suresh j, Thongsawat, Satawat k, Thetket, Kanawee l, Avihingsanon, Anchalee m, n, Khemnark, Suparat o, Yerly, Sabine p, Ngo-Giang-Huong, Nicole d, q, Siva, Sasikala r, Swanson, Alistair a, Goyal, Vishal s, Bompart, Francois a, Pécoul, Bernard a, Murad, Shahnaz t
Zdroj: In The Lancet Gastroenterology & Hepatology June 2021 6(6):448-458
Databáze: ScienceDirect